

## MYOBLOC® PREMIER PARTNER QUICK GUIDE

FOR CERVICAL DYSTONIA  
& CHRONIC SIALORRHEA  
IN ADULTS

MY COMMITMENT.  
MY PATIENTS.  
MYOBLOC.

Not actual healthcare providers.

### INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

### IMPORTANT SAFETY INFORMATION

#### WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

Please refer to the full [Prescribing Information](#), and additional Important Safety Information throughout, and on next page.

## RESOURCES

### YOUR PREMIER PARTNER BENEFITS

As a MYOBLOC Premier Partner, you enjoy:



Up to 10% savings  
with volume-based  
pricing



Direct-line access  
to our medical team  
for questions or  
information



Billing and  
coding support

Access your benefits in the Premier Partner Hub



### FIELD ACCESS SPECIALISTS

Supernus Field Access Specialists provide in-office assistance and education to staff and physicians upon request regarding:

- Reimbursement
- Insurance and government guidelines/policies
- Billing and coding

For more information on ordering and reimbursement,  
call 1-888-461-2255 or visit MYOBLOChcp.com



### CIRCLE OF CARE™ PORTAL:

Log in and register at [hcp.supernusconnect.com](http://hcp.supernusconnect.com)

- Each practice is assigned a Circle of Care Case Manager who assists in the benefit investigation, prior authorization, specialty pharmacy communication, and/or Patient Assistance Program application for MYOBLOC
- Online submission for insurance benefit investigations and prior authorizations for new and current MYOBLOC patients
- 2-business-day turnaround for most benefit investigations
- Prior authorization assistance, if required
- Real-time patient status updates

Watch a video on how to use the Circle of Care Portal



### WHAT PATIENT TYPES ARE RIGHT FOR MYOBLOC?

Whether you are a frequent injector or a new injector of MYOBLOC, see possible patient types who could be appropriate to treat with MYOBLOC.

Download full patient profiles



### IMPORTANT SAFETY INFORMATION (cont'd) CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:


- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

Please refer to the full [Prescribing Information](#), including [Boxed WARNING](#), and additional Important Safety Information on next page.

## DOSING GUIDE FOR CERVICAL DYSTONIA

DOSING IS BASED ON CLINICAL TRIALS

TOTAL DOSE DIVIDED AMONG 2 TO 4 AFFECTED MUSCLES<sup>1</sup>



Muscle	Starting Dose Range	Undiluted Volume
LEVATOR SCAPULAE	1,000 – 2,500 Units	0.2 – 0.5 mL
SCALENE COMPLEX	500 – 1,000 Units	0.1 – 0.2 mL
SEMI SPINALIS CAPITIS	1,000 – 2,500 Units	0.2 – 0.5 mL
SPLЕНИUS CAPITIS	1,000 – 2,500 Units	0.2 – 0.5 mL
STERNOCLEIDOMASTOID	1,000 – 2,500 Units	0.2 – 0.5 mL
TRAPEZIUS	1,000 – 2,500 Units	0.2 – 0.5 mL

### DOSING RECOMMENDATIONS<sup>1</sup>:

- The recommended initial total dose of MYOBLOC for patients with a prior history of tolerating botulinum toxin injections is 2,500 to 5,000 Units, divided among affected muscles
- Patients without a prior history of tolerating botulinum toxin injections should receive a lower initial dose
- Subsequent dosing should be determined by the patient's individual response

### DOSING CONSIDERATIONS:

- Patient weight and muscle bulk
- Cervical dystonia symptom severity
- Risk of swallowing or breathing difficulties in patients with neuromuscular disorders<sup>1</sup>
- Reduction of dosage is called for in patients with smaller neck muscles and who require bilateral injections into the sternocleidomastoid
- The duration of effect has been observed in studies to be between 12 and 16 weeks at doses of 5,000 Units or 10,000 Units<sup>1</sup>


### IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS

#### ▪ Lack of Interchangeability Between Botulinum Toxin Products

The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

## DOSING GUIDE FOR CHRONIC SIALORRHEA

ANATOMICAL TREATMENT<sup>1</sup>



Gland	Starting Dose Range (units)	Undiluted Volume (mL)
Parotid Injection Site 1	500 - 1,500 per gland	0.1 - 0.3 per gland
Submandibular Injection Site 2	250 per gland	0.05 per gland

### DOSING RECOMMENDATIONS<sup>1</sup>:

- Subsequent dosing and frequency of dosing should be optimized according to the patient's individual response
  - Generally, no more frequent than every 12 weeks
  - Individual patient responses may vary

### DOSING CONSIDERATIONS<sup>1</sup>:

- Sialorrhea symptom severity
- Risk of swallowing or breathing difficulties in patients with neuromuscular disorders

See additional data and download indication-specific dosing guides



Please refer to the full **Prescribing Information**, including **Boxed WARNING**, and additional **Important Safety Information** on next page.

## BILLING INFORMATION

Condition	Code	Description
Cervical dystonia*	ICD10 - G24.3	Spasmodic torticollis (CD)
	CPT - 64616	Chemodeneration of muscle(s), cervical spinal muscle(s); 50 modifier for bilateral injections
	J0587	MYOBLOC is billed in 100 units (ie, 5,000 units = 50 units billed)
	95873	Electrical stimulation for guidance in conjunction with chemodeneration
	95874	Needle electromyography for guidance in conjunction with chemodeneration
	76942	Ultrasonic guidance for needle placement imaging
Chronic sialorrhea*	ICD10 - K11.7	Disturbances of salivary secretion (sialorrhea)
	CPT - 64611	Chemodeneration of parotid and submandibular salivary glands, bilateral
	J0587	MYOBLOC is billed in 100 units (ie, 5,000 units = 50 units billed)
	76942	Ultrasonic guidance for needle placement imaging

Medicare contractors require the modifier JW to identify unused drugs or biologics from single-use vials or single-use packages that are appropriately discarded. This modifier, billed on a separate claim line, supports payment for the amount of discarded drug or biologic.

For more information on billing and coding, visit [Myoblochcp.com](https://myoblochcp.com)




\*Table contains possible appropriate codes for cervical dystonia and chronic sialorrhea.

Please refer to the full **Prescribing Information**, including **Boxed WARNING**, and additional **Important Safety Information** on next page.

## HOW THE CIRCLE OF CARE™ HELPS DR. BAHROO

For 23 years and counting, we are proud to partner with healthcare providers like you to help appropriate adult patients with cervical dystonia or chronic sialorrhea.

Learn about how being a Premier Partner and the Circle of Care have helped Dr. Bahroo, a movement disorder specialist and MYOBLOC prescriber based out of Washington, DC.



**"If my office has a billing question or a concern about the process, they can reach out to the MYOBLOC Circle of Care team."**

— DR. LAXMAN BAHROO, DO

Hear the full story



### IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS (cont'd)

• **Hypersensitivity Reactions**

Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.



## IMPORTANT SAFETY INFORMATION

### WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

### CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

### WARNINGS AND PRECAUTIONS

#### ▪ Lack of Interchangeability Between Botulinum Toxin Products

The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

#### ▪ Hypersensitivity Reactions

Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.

#### ▪ Dysphagia and Breathing Difficulties

Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.

– **Cervical Dystonia:** Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

– **Pre-Existing Neuromuscular Disorders:** Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.

#### ▪ Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

### MOST COMMON ADVERSE REACTIONS (>5% of patients and >5% more than placebo)

**Cervical Dystonia:** dry mouth, dysphagia, injection site pain, headache

**Chronic Sialorrhea:** dry mouth, dysphagia

### DRUG INTERACTIONS

**Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission:** Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. **Anticholinergic Drugs:** Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects. **Other Botulinum Neurotoxin Products:** The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. **Muscle Relaxants:** Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

## INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

**REFERENCE: 1.** MYOBLOC. Prescribing Information. Solstice Neurosciences, LLC.

Please refer to the enclosed full [Prescribing Information](#), including [Boxed WARNING](#).



Not actual  
healthcare providers.

# MY TIME. MY RESOURCES. MYOBLOC.

For additional MYOBLOC materials, please reach out to your Field Access Specialist.



Visit our Premier Partners Hub for the full menu of practice benefits available.



To order MYOBLOC, call 1-888-461-2255, Option 1.



## INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

## IMPORTANT SAFETY INFORMATION

### WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

Please refer to the full Prescribing Information, including Boxed WARNING, and additional Important Safety Information on page 5.

MYOBLOC is a registered trademark of Solstice Neurosciences, LLC, a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc.  
© 2024. Supernus Pharmaceuticals, Inc. MYO.2024-0026.

